Tweet
Transpl Immunol
. 2021 Aug 9;101445.
doi: 10.1016/j.trim.2021.101445. Online ahead of print.
Summary report of seven cases of COVID-19 infection in renal transplant recipients
Tianyu Wang 1 , Tao Qiu 1 , Yan Yuan 2 , Zhongbao Chen 1 , Xiaoxiong Ma 1 , Long Zhang 1 , Zeya Jin 1 , Jilin Zou 1 , Yalong Zhang 1 , Jiangqiao Zhou 3
Affiliations
- PMID: 34384886
- DOI: 10.1016/j.trim.2021.101445
Abstract
The coronavirus disease 2019 (COVID-19) has swept the world, posing a serious threat to people's lives and health. Several cases of COVID-19 infection in renal transplant recipients (RTRs) have been reported, but the treatment and prognosis have not been fully elucidated. We followed-up with RTRs infected with SARS-CoV2 in our center and classified them as five clinical types-asymptomatic, mild, moderate, severe, and critical. The immunosuppressive agents were not adjusted in asymptomatic carriers and mild patients, the former was mainly treated by isolation, and the latter was treated by low-dose intravenous immunoglobulin (IVIG) to enhance immunity. For moderate or severe patients, the immunosuppressive agents were largely reduced or even interrupted, low-dose IVIG was adopted, and low-dose methylprednisolone (MP) was used to inhibit inflammation and rejection. Immunosuppressants were discontinued early in critical patients; IVIG, high-dose MP, and antibiotics were used. Meanwhile, all patients received at least one antiviral drugs. After aggressive treatment, three patients developed acute kidney injury, and two showed reversal, while the remaining one lost the allograft kidney; one patient died, while other patients were discharged. For different clinical types of RTRs infected with COVID-19, personalized therapies were essential, Meanwhile, patients with COVID-19 infection may have different outcomes due to their different clinical manifestations.
Keywords: COVID-19; Management; Renal transplant; SARS-CoV-2; Treatment.